Wieland Capital

Wieland Capital is an entrepreneurial family office based in Munich, Germany, that has been investing its own family wealth for nearly two decades. The firm focuses on long-term, reliable, and entrepreneurial investments across various asset classes. They primarily target established medium-sized, profitable companies in German-speaking countries, emphasizing a strong and motivated management team. While operating mainly in the DACH region, Wieland Capital maintains a deliberately industry-agnostic approach to its private equity investments.

The firm was founded in 2004 by Robert Wieland, following the sale of ESPE, a dental company established by his grandfather. This entrepreneurial heritage underpins Wieland Capital’s investment philosophy, which prioritizes sustainable value creation through operational performance rather than solely financial engineering. They typically invest alongside founders and management teams, often in the context of company succession, with equity commitments per transaction generally ranging from €2 million to €7 million. For larger deals, they collaborate with co-investors.

Wieland Capital’s diverse portfolio includes investments in sectors such as Biotechnology & Life Sciences (e.g., Peptido, Lifespin, noscendo, PhagoMed, Dawn-Bio, Cycuria Therapeutics), Healthcare, Healthtech & Medtech (e.g., Care), Industrials (e.g., HKT-Kabeltechnik, Ceranovis, i3 Membrane, Inductio), Technology, Software & Gaming (e.g., RoamsysNext, Schlafender Hase), Consumer (e.g., REMEMBER), and Materials, Chemicals & Natural Resources (e.g., Plasmion). Beyond private equity and venture capital, the firm also invests in real estate, focusing on existing residential properties in good condition in cities like Berlin, Leipzig, and Dresden, as well as forestry and other liquid and illiquid assets.

The leadership team at Wieland Capital brings extensive experience to their investment activities. Robert Wieland, a founding partner, has a background in M&A consulting at Credit Suisse First Boston and Donaldson, Lufkin & Jenrette. Franck Godet, also a partner, contributes over a decade of investment banking experience from BNP Paribas, Credit Suisse First Boston, and Donaldson, Lufkin & Jenrette. Melissa Simon, who joined in 2023, adds specialized investment expertise in Pharma, Life Science, and Health Tech from her previous role at a large family office in Munich. The partners are actively involved as informed and engaged shareholders, fostering collaborative partnerships with management teams to drive the sustainable development of their portfolio companies.